Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.69 | -0.57 | 2.81 | 2.10 |
| FCF Yield | -1.56% | -1.33% | -2.13% | -1.59% |
| EV / EBITDA | -54.80 | -49.93 | -39.59 | -54.31 |
| Quality | ||||
| ROIC | -13.64% | -12.11% | -14.93% | -11.65% |
| Gross Margin | 0.00% | 81.76% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.73 | -9.29 | 7.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,020,193.39% | 2,020,193.39% | -100.00% | -100.00% |
| Free Cash Flow Growth | -21.99% | -34.42% | 7.86% | 16.67% |
| Safety | ||||
| Net Debt / EBITDA | -0.34 | 3.70 | -2.28 | -1.99 |
| Interest Coverage | -53.79 | -52.73 | -42.10 | -36.68 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.00 | -0.43 | -0.33 |
| Cash Conversion Cycle | -151.62 | -652.14 | -928.57 | -899.60 |